Best of ASCO - 2014 Annual Meeting

 

Welcome

Conduct of Clinical Research

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
#earlydetection: Leveraging social media to recruit individuals at increased-risk of pancreas cancer for an early detection study.

Kelsey Klute

e14577

A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.

Gary Edward Richardson

TPS3150

A phase I multiple-dose escalation study to assess the safety, tolerability, and pharmacokinetics of VEGF-receptor inhibitor telatinib (EOC315) in Chinese patients with advanced solid tumors.

Hongming Pan

3061

Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors.

Irene Brana

TPS3151

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Tae Won Kim

3000

Business versus science: High drug prices conspire against oncological research.

Felipe G. Gercovich

e14580

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers.

Nicola Jane Lawrence

e14576

Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.

James V. Tricoli

3016

Effectiveness of ASCO’s adverse event reporting decision aid: Results from an interventional study.

Kathryn Finch Mileham

3065

Feasibility of a platform trial based on molecular analysis in rare gynecologic cancers.

Jubilee Brown

e14585

First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.

Debbie Robbrecht

3063

Is the optimal biological dose of oncologic molecular-targeted therapies also clinically effective?

Pauline Corbaux

3060

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.

Martijn P. Lolkema

3062

Moving away from the boilerplate: Real-world evidence for clinical trial laboratory criteria.

David Hadley

e14581

Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.

Junning Cao

3059

Prognostic value of serum apolipoprotein B (ApoB) to apolipoprotein A-I (ApoA-I) ratio in hepatocellular carcinoma patients with transcatheter arterial chemoembolization treatment: propensity score-matched analysis.

Meng meng Liu

e14589

Rethinking about the dose limiting toxicities (DLTs): They can be equivocal!

Wei Zhong

3064

Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.

Arjun Mittra

3067

The host response to immune checkpoint inhibitors: From mechanisms to therapeutic implications.

Ella Fremder

e14584

The i3+3 design for phase I clinical trials.

Yuan Ji

3066

The relationship between response and dose in published, contemporary phase 1 oncology trials.

Antonious Ziad Hazim

e14583

Trends in case-control allocation in phase III randomized cancer clinical trials.

Shruti Gupta

e14582

Trial in progress abstract phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

M. Cecilia Monge B.

TPS3148

Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.

Jade Maxime van Berge Henegouwen

TPS3149

Use of a clinical trials screening tool in the NCI Community Oncology Research Program (NCORP) to enhance accrual and promote disparities research.

Diane C. St. Germain

e14587